Aspirin Effectiveness Study

Royal College of Surgeons, Ireland500 enrolled

Overview

Aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. In previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in Ireland. This study is being done to identify the percentage of patients in Ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in Irish patients.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older * Patients with documented coronary artery disease * Current treatment with any dose of aspirin daily for a minimum of 3 months * Able to provide written informed consent based on competent mental status Exclusion Criteria: * Myocardial infarction, unstable angina or stroke during the preceding three months * Platelet count \<125,000/mm * Known haematological disorders * Active malignancy on current chemotherapy or a recent diagnosis of cancer

Locations (1)

Beaumont Hospital

Dublin, Dublin, Ireland

RECRUITING

Outcomes

Primary Outcomes

Percentage of patients with non-response to aspirin

Prevalence of non-response to aspirin in coronary artery disease patients in Ireland by measurement of serum thromboxane B2

Time frame: Following a minimum of 3 months of daily aspirin use

Central Contacts

Mary C De Voe, RN

CONTACT

+353-21 4901442 m.devoe@ucc.ie

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.